Literature DB >> 33422414

Breast cancer radioresistance may be overcome by osteopontin gene knocking out with CRISPR/Cas9 technique.

R G Behbahani1, A Danyaei2, A Teimoori3, N Neisi4, M J Tahmasbi1.   

Abstract

PURPOSE: Osteopontin (OPN) is a phosphoglycoprotein, with a wide range of physiological and pathological roles. High expression of OPN promotes aggressive behavior, causes poor prognosis in tumor cells, and reduces the survival of patients. Since overexpression of OPN gives rise to radioresistance, the effects of the gene knock out using the CRISPR/Cas9 system in combination with radiation are emphasized.
MATERIAL AND METHODS: We used the CRISPR/Cas9 technique to knock out the OPN gene in the MDA-MB-231 cell line. After transfection, the cells were irradiated. The changes of the OPN mRNA levels, the apoptosis, and the differences in cell viability were assessed.
RESULTS: A significant reduction in the OPN expression was observed alone or along with irradiation. The knocked out gene alone increased apoptosis rate. The cell viability decreased to after knocking out of the OPN gene. The gene knocking-out combined with irradiation led to more decline of cell viability.
CONCLUSION: Our results demonstrated that after knocking out the OPN gene, the MDA-MB-231 cells showed a significant radiosensitivity. Therefore, the OPN knock out in combination with conventional radiotherapy, may become an efficient therapeutic target in the future.
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Breast cancer; CRISPR/Cas 9; Cancer du sein; Osteopontin; Ostéopontine; Radiotherapy; Radiothérapie

Year:  2021        PMID: 33422414     DOI: 10.1016/j.canrad.2020.08.048

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  5 in total

1.  CRISPR/Cas9 mediated knocking out of OPN gene enhances radiosensitivity in MDA-MB-231 breast cancer cell line.

Authors:  Rahil Ghanbarnasab Behbahani; Amir Danyaei; Ali Teimoori; Mohammad Javad Tahmasbi; Niloofar Neisi
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

Review 2.  CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Authors:  Fatima Akram; Ikram Ul Haq; Sania Sahreen; Narmeen Nasir; Waqas Naseem; Memoona Imitaz; Amna Aqeel
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 3.  Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.

Authors:  Mohammed Fatih Rasul; Bashdar Mahmud Hussen; Abbas Salihi; Bnar Saleh Ismael; Paywast Jamal Jalal; Anna Zanichelli; Elena Jamali; Aria Baniahmad; Soudeh Ghafouri-Fard; Abbas Basiri; Mohammad Taheri
Journal:  Mol Cancer       Date:  2022-03-03       Impact factor: 27.401

Review 4.  Identification of Novel Regulators of Radiosensitivity Using High-Throughput Genetic Screening.

Authors:  Rosette N Tamaddondoust; Alicia Wong; Megha Chandrashekhar; Edouard I Azzam; Tommy Alain; Yi Wang
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

5.  A Four-Gene Signature Associated with Radioresistance in Head and Neck Squamous Cell Carcinoma Identified by Text Mining and Data Analysis.

Authors:  Yongqian Zhang; Hongmin Wang; Feifei Wang; Wenhua Ma; Na Li; Changwen Bo; YingChun Zhao; Li He; Ming Liu
Journal:  Comput Math Methods Med       Date:  2022-09-27       Impact factor: 2.809

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.